Comparing Mounjaro and Ozempic for Weight Loss Effectiveness

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Neither Mounjaro nor Ozempic is FDA approved for weight loss — both are approved for type 2 diabetes, and any comparison of their "weight loss effectiveness" is a comparison of secondary outcomes from diabetes trials. The Mounjaro prescribing information states it is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The Ozempic prescribing information lists three indications, all in adults with type 2 diabetes: glycemic control, cardiovascular risk reduction in those with established cardiovascular disease, and kidney and cardiovascular risk reduction in those with chronic kidney disease. With that established, there is a genuine head-to-head trial, and it favored tirzepatide.

The Two Molecules Do Not Work the Same Way

Ozempic is semaglutide, a selective glucagon-like peptide-1 receptor agonist. Mounjaro is tirzepatide, which the Lilly label describes as a GIP receptor and GLP-1 receptor agonist that selectively binds to and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner.

Glucose-dependent insulinotropic polypeptide and GLP-1 are both incretin hormones released from the gut after eating. Adding a second receptor target is the structural difference between the two drugs, and it is the most plausible explanation for the difference in observed effect sizes. It is not a guarantee of a better result in any given person — it is a mechanistic difference that showed up as a difference in trial averages.

The Head-to-Head Trial: SURPASS-2

The direct comparison exists. SURPASS-2 was an open-label, 40-week phase 3 trial that randomized 1,879 patients with type 2 diabetes in a 1:1:1:1 ratio to tirzepatide 5 mg, 10 mg or 15 mg, or semaglutide 1 mg, all once weekly. Mean baseline glycated hemoglobin was 8.28% and mean baseline weight was 93.7 kg.

The primary endpoint was glycemic. Estimated mean reductions in glycated hemoglobin were 2.01, 2.24 and 2.30 percentage points across the three tirzepatide doses versus 1.86 percentage points with semaglutide; tirzepatide was noninferior and superior at all doses. Reductions in body weight were also greater with tirzepatide, with least-squares mean estimated treatment differences of −1.9 kg, −3.6 kg and −5.5 kg versus semaglutide. Gastrointestinal events were the most common adverse events in both groups and were primarily mild to moderate.

Reading That Result Carefully

Three caveats change how much weight the comparison can bear. The semaglutide comparator was dosed at 1 mg, which is a Ozempic-range dose, not the higher doses studied for weight management. The trial ran 40 weeks, which is shorter than the 72-week obesity trials. And every participant had type 2 diabetes — a population in which incretin therapies consistently produce less weight reduction than in people without diabetes.

So SURPASS-2 answers a narrow question well: among adults with type 2 diabetes, over 40 weeks, at those doses, tirzepatide lowered glycated hemoglobin more and reduced weight more than semaglutide 1 mg. It does not answer whether one drug is a better obesity treatment, because it was not designed to.

The Weight-Management Approvals Belong to Different Brands

Tirzepatide does hold a weight-management approval — under the brand name Zepbound, not Mounjaro. The FDA approved Zepbound on November 8, 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Semaglutide's weight-management approval belongs to Wegovy, whose labeling covers cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, reduction and long-term maintenance of excess body weight in adults and in patients aged 12 and older with obesity, and noncirrhotic MASH with moderate to advanced liver fibrosis under accelerated approval.

This is why the framing matters. Regulatory approval attaches to an application supported by specific trials, not to a molecule. Same ingredient, different application, different label, and frequently different insurance treatment.

What the Obesity Trials Showed

SURMOUNT-1 studied tirzepatide in 2,539 adults with obesity or overweight, explicitly excluding diabetes, over 72 weeks. Mean weight change at week 72 was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg doses versus −3.1% with placebo, and 57% of the 15 mg group lost at least 20% of body weight versus 3% on placebo.

The cleanest obesity comparison came later. SURMOUNT-5, a phase 3b open-label trial, randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) for 72 weeks. Least-squares mean percent weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm. Both differences were statistically significant. That trial compares the weight-management doses, which is the comparison most readers are actually looking for.

Averages Are Not Predictions

Every number above is a group mean. Within the same trial arm, some participants lost a quarter of their body weight and others lost almost none. A trial that shows a 6.5-percentage-point difference in group averages does not tell you that you will lose 6.5 percentage points more on one drug than the other.

Tolerability cuts the same way. Gastrointestinal effects dominated the adverse event profile in every one of these trials, and the drug that produces the larger average reduction is not necessarily the one an individual can stay on. Effectiveness that cannot be sustained is not effectiveness.

Compounded Preparations Are Not These Products

Compounded semaglutide and compounded tirzepatide are not FDA-approved finished products, and the FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. They are prepared by licensed pharmacies pursuant to prescriptions for individual patients. Mounjaro, Zepbound, Ozempic and Wegovy are the approved brands, and a compounded preparation is not a generic version of any of them.

Which product is appropriate — and whether either is — is a determination for a licensed prescriber who can see your diagnoses, your other medications and your history. No comparison table substitutes for that.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro or Ozempic better for weight loss?

Neither is FDA approved for weight loss; both are approved for type 2 diabetes. In SURPASS-2, the 40-week head-to-head trial in 1,879 adults with type 2 diabetes, tirzepatide produced greater weight reduction than semaglutide 1 mg, with treatment differences of −1.9 kg, −3.6 kg and −5.5 kg across three doses. Those are group averages in a diabetes population and do not predict any individual result.

Are Mounjaro and Ozempic the same type of drug?

No. Ozempic is semaglutide, a selective GLP-1 receptor agonist. Mounjaro is tirzepatide, which the label describes as a GIP receptor and GLP-1 receptor agonist that activates both receptors. That second target is the structural difference between them and the most plausible explanation for the larger average effects seen with tirzepatide in head-to-head trials.

Which trial compared the weight-management doses directly?

SURMOUNT-5, a phase 3b open-label trial, randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg) for 72 weeks. Least-squares mean weight change at week 72 was −20.2% with tirzepatide versus −13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm.

Why does my insurance cover one but not the other?

Coverage usually follows the approved indication rather than the active ingredient. Mounjaro and Ozempic are approved for type 2 diabetes; Zepbound and Wegovy hold the weight-management approvals. Prior authorization criteria, diagnosis coding and formulary placement all key off those indications, which is why the same person can be approved for one product and denied another containing a related molecule.

Is compounded tirzepatide the same as Mounjaro?

No. Compounded tirzepatide is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Mounjaro or Zepbound, because no approved generic of either exists.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.